Your browser doesn't support javascript.
loading
Influence of plasma matrix metalloproteinase levels on longitudinal changes in Alzheimer's disease (AD) biomarkers and cognitive function in patients with mild cognitive impairment due to AD registered in the Alzheimer's Disease Neuroimaging Initiative database.
Abe, Kie; Chiba, Yuhei; Hattori, Saki; Yoshimi, Asuka; Asami, Takeshi; Katsuse, Omi; Suda, Akira; Hishimoto, Akitoyo.
Afiliación
  • Abe K; Department of Psychiatry, Yokohama City University Graduate School of Medicine, Japan.
  • Chiba Y; Department of Psychiatry, Yokohama City University Graduate School of Medicine, Japan. Electronic address: suezan_2000@yahoo.co.jp.
  • Hattori S; Department of Psychiatry, Yokohama City University Graduate School of Medicine, Japan.
  • Yoshimi A; Department of Psychiatry, Yokohama City University Graduate School of Medicine, Japan.
  • Asami T; Department of Psychiatry, Yokohama City University Graduate School of Medicine, Japan.
  • Katsuse O; Department of Psychiatry, Yokohama City University Graduate School of Medicine, Japan.
  • Suda A; Department of Psychiatry, Yokohama City University Graduate School of Medicine, Japan.
  • Hishimoto A; Department of Psychiatry, Yokohama City University Graduate School of Medicine, Japan.
J Neurol Sci ; 416: 116989, 2020 Sep 15.
Article en En | MEDLINE | ID: mdl-32603972
OBJECTIVE: The present study investigated the effects of plasma matrix metalloproteinases (MMPs) on longitudinal changes in Alzheimer's disease (AD)-related biomarkers in cerebrospinal fluid (CSF), brain atrophy, and cognitive function in patients with mild cognitive impairment due to AD (MCI-AD). METHODS: We used data from the Alzheimer's Disease Neuroimaging Initiative database. We included 95 ApoE4-positive patients with MCI-AD who were confirmed to have low Aß42 and/or high phosphorylated-tau (p-tau) in CSF. We obtained baseline demographic data, plasma MMP levels, including MMP-1, -2, -7, -9, -10, and tissue inhibitor of MMP-1 (TIMP-1), longitudinal annual data on Aß42, total tau, and p-tau in CSF, MRI-measured hippocampal volumes, and cognitive function evaluated by the Mini-Mental State Examination (MMSE) and AD Assessment Scale-11 (ADAS-11) over 4 years. We examined the effects of baseline MMP levels on longitudinal changes in CSF AD biomarkers, hippocampal volumes, and cognitive function using a linear mixed regression analysis. RESULTS: No significant differences were observed in baseline plasma MMP levels between MCI-AD patients and control subjects, except for MMP-10, which was significantly lower in MCI-AD than in controls. The baseline levels of MMPs did not correlate with longitudinal changes in CSF biomarkers. Declines in hippocampal volumes and cognitive function evaluated by MMSE and ADAS-11 were significantly faster in MCI-AD patients with high-MMP-9 levels at baseline than in those with middle and low MMP-9 levels at baseline. CONCLUSION: High plasma MMP-9 levels in MCI-AD patients might enhance neurodegeneration and cognitive decline.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Enfermedad de Alzheimer / Disfunción Cognitiva Tipo de estudio: Etiology_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: J Neurol Sci Año: 2020 Tipo del documento: Article País de afiliación: Japón Pais de publicación: Países Bajos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Enfermedad de Alzheimer / Disfunción Cognitiva Tipo de estudio: Etiology_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: J Neurol Sci Año: 2020 Tipo del documento: Article País de afiliación: Japón Pais de publicación: Países Bajos